hTERT mRNA levels by real‐time RT‐PCR in acute myelogenous leukemia
hTERT mRNA levels by real‐time RT‐PCR in acute myelogenous leukemia
复制标题
DOI：
10.1002/ajh.20394
复制
发表时间：
2005-08
影响因子：
12.8
通讯作者：
H. Huh;J. Huh;E. Yoo;C. Seong;Miae Lee;K. Hong;W. Chung
中科院分区：
文献类型：
--
作者：
H. Huh;J. Huh;E. Yoo;C. Seong;Miae Lee;K. Hong;W. Chung
本研究的目的是研究hTERT mRNA水平（通过真实的实时RT-PCR测定）是否与AML患者的预后和临床病程相关。纳入了来自21例诊断为新发AML患者的54份骨髓标本。使用LightCycler仪器（Roche Diagnostics），用Telo TAGGG hTERT定量试剂盒（Roche Diagnostics，曼海姆，德国）测量hTERT mRNA的水平。hTERT mRNA的水平被确定为相对比率（RR），其通过将相同样品中hTERT mRNA的水平除以胆色素原脱氨酶（PBGD）管家基因的水平[1，000 ×（hTERT/PBGD）]来计算。hTERTmRNA在初发期（73%）和复发期（80%）的表达率明显高于缓解期（27%）（P0.05）。2例缓解期hTERTmRNA表达的患者（RR分别为3.14和7.15）在1个月后复发。7例hTERTmRNA高表达患者（RR > 9.51）中4例未达完全缓解（CR），而5例hTERTmRNA表达阴性或复发患者中4例达CR（P > 0.05）。表现出hTERTmRNA水平增加趋势的患者在复发后未能达到第二次CR，而具有hTERTmRNA降低趋势的患者确实达到CR。在缓解期（RR > 0）显示hTERTmRNA表达的8个样品中，5个来自在14天内接受GCSF的患者。GSCF治疗组缓解期hTERTmRNA表达率和表达水平（56%，RR = 0.15）明显高于其他组（15%，RR = 0）（P < 0.05）。hTERTmRNA的连续定量分析可作为AML患者预后预测和病情监测的一个有用指标。Am. J. Hematol.© 2005 Wiley利斯公司。
The purpose of this study was to investigate whether levels of hTERT mRNA, as determined by real‐time RT‐PCR, are associated with prognosis and clinical course in AML patients. Fifty‐four bone marrow specimens from 21 patients diagnosed with de‐novo AML were included. The level of hTERT mRNA was measured with the Telo TAGGG hTERT Quantification Kit (Roche Diagnostics, Mannheim, Germany), using a LightCycler Instrument (Roche Diagnostics). The level of hTERT mRNA was determined as the relative ratio (RR), which was calculated by dividing the level of hTERT mRNA by the level of the porphobilinogen deaminase (PBGD) housekeeping gene in the same samples [1,000 × (hTERT/PBGD)]. The expression rates of hTERT mRNA were significantly higher at diagnosis (73%) and during relapse (80%) than during remission (27%) (P 0.05). Two patients who showed hTERT mRNA expression during remission (RR 3.14 and 7.15, respectively) relapsed after 1 month. Among seven patients with high hTERT mRNA levels (RR > 9.51), 4 failed to achieve complete remission (CR), whereas 4 of 5 patients without hTERT mRNA expression at diagnosis or during relapse achieved CR (P > 0.05). Patients showing a trend of increasing hTERT mRNA levels failed to reach a second CR after relapse, while those with a trend toward decreasing hTERT mRNA did achieve CR. Among eight samples showing hTERT mRNA expression in remission (RR > 0), 5 were obtained from patients who had received GCSF within 14 days. The expression rate and level of hTERT mRNA during remission were significantly higher in patients who had previously received GSCF (56%, RR = 0.15) than in other patients (15%, RR = 0) (P < 0.05). Serial and quantitative analysis of hTERT mRNA may be a useful marker for prediction of prognosis and monitoring in AML patients. Am. J. Hematol. 79:267–273, 2005.© 2005 Wiley‐Liss, Inc.